KRAS and non-small cell lung carcinoma: The second study that contained granular co-mutation outcomes (KRAS G12D) demonstrated statistically worse PFS for NSCLC patients; PFS: SMARCA4/KRAS G12D-co-mutated (N = 8) vs. SMARCA4 WT/KRAS G12D-mutated (N = 49) (1.5 vs. 4.0 months; p = 0.0039) [34].